(ALT) Altimmune - Overview
Stock: Obesity, Mash, Liver, Metabolic, Agonist
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 102% |
| Relative Tail Risk | -17.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.14 |
| Alpha | -49.79 |
| Character TTM | |
|---|---|
| Beta | 1.331 |
| Beta Downside | 0.771 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.07% |
| CAGR/Max DD | -0.34 |
Description: ALT Altimmune December 26, 2025
Altimmune, Inc. (NASDAQ: ALT) is a clinical-stage biotech focused on obesity, metabolic and liver disorders. Its flagship candidate, pemvidutide-a GLP-1/glucagon dual-receptor agonist-is in a Phase 3 trial targeting both obesity and metabolic-associated steatohepatitis (MASH). The company, founded in 1997, is headquartered in Gaithersburg, Maryland, and trades as a common stock in the U.S. biotechnology sub-industry.
Key quantitative points (as of the most recent filings) include a market capitalization of roughly $200 million, cash and short-term investments of about $80 million, giving a runway of roughly 12-18 months at current burn rates. The global obesity therapeutics market is projected to grow at a CAGR of ~ 7 % through 2030, driven by rising prevalence of obesity and expanding insurance coverage for GLP-1-based treatments. Altimmune’s Phase 3 enrollment is ~ 1,200 patients, and interim data released in Q2 2024 showed a mean weight loss of 12 % versus 3 % for placebo, though the full statistical significance and safety profile remain pending.
If you’re evaluating biotech pipelines, a quick look at ValueRay’s analyst notes on ALT can help surface additional risk factors and upside scenarios worth deeper investigation.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -83.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.31 > 0.02 and ΔFCF/TA 22.31 > 1.0 |
| NWC/Revenue: 1.02m% < 20% (prev 263.7k%; Δ 756.4k% < -1%) |
| CFO/TA -0.31 > 3% & CFO -66.7m > Net Income -83.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (89.4m) vs 12m ago 25.79% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.01% > 50% (prev 0.04%; Δ -0.02% > 0%) |
| Interest Coverage Ratio: -110.2 > 6 (EBITDA TTM -83.7m / Interest Expense TTM 761.0k) |
Altman Z'' -15.00
| A: 0.93 (Total Current Assets 216.6m - Total Current Liabilities 12.6m) / Total Assets 218.4m |
| B: -2.85 (Retained Earnings -622.1m / Total Assets 218.4m) |
| C: -0.46 (EBIT TTM -83.8m / Avg Total Assets 183.2m) |
| D: -19.09 (Book Value of Equity -627.1m / Total Liabilities 32.8m) |
| Altman-Z'' Score: -26.28 = D |
Beneish M -4.00
| DSRI: 0.11 (Receivables 145.0k/3.34m, Revenue 20.0k/52.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.0 (AQ_t 0.0 / AQ_t-1 0.01) |
| SGI: 0.38 (Revenue 20.0k / 52.0k) |
| TATA: -0.08 (NI -83.9m - CFO -66.7m) / TA 218.4m) |
| Beneish M-Score: -4.87 (Cap -4..+1) = AAA |
What is the price of ALT shares?
Over the past week, the price has changed by -13.04%, over one month by +22.98%, over three months by +23.60% and over the past year by -29.52%.
Is ALT a buy, sell or hold?
- StrongBuy: 5
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ALT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.7 | 262.8% |
| Analysts Target Price | 17.7 | 262.8% |
| ValueRay Target Price | 4.1 | -16.8% |
ALT Fundamental Data Overview February 03, 2026
P/B = 3.4411
Revenue TTM = 20.0k USD
EBIT TTM = -83.8m USD
EBITDA TTM = -83.7m USD
Long Term Debt = 14.4m USD (from longTermDebt, last quarter)
Short Term Debt = 247.0k USD (from shortTermDebt, last quarter)
Debt = 15.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -45.3m USD (from netDebt column, last quarter)
Enterprise Value = 506.4m USD (701.3m + Debt 15.9m - CCE 210.8m)
Interest Coverage Ratio = -110.2 (Ebit TTM -83.8m / Interest Expense TTM 761.0k)
EV/FCF = -7.60x (Enterprise Value 506.4m / FCF TTM -66.7m)
FCF Yield = -13.16% (FCF TTM -66.7m / Enterprise Value 506.4m)
FCF Margin = -333.3k% (FCF TTM -66.7m / Revenue TTM 20.0k)
Net Margin = -419.6k% (Net Income TTM -83.9m / Revenue TTM 20.0k)
Gross Margin = unknown ((Revenue TTM 20.0k - Cost of Revenue TTM 15.0m) / Revenue TTM)
Tobins Q-Ratio = 2.32 (Enterprise Value 506.4m / Total Assets 218.4m)
Interest Expense / Debt = 3.11% (Interest Expense 495.0k / Debt 15.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -66.2m (EBIT -83.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.18 (Total Current Assets 216.6m / Total Current Liabilities 12.6m)
Debt / Equity = 0.09 (Debt 15.9m / totalStockholderEquity, last quarter 185.6m)
Debt / EBITDA = 0.54 (negative EBITDA) (Net Debt -45.3m / EBITDA -83.7m)
Debt / FCF = 0.68 (negative FCF - burning cash) (Net Debt -45.3m / FCF TTM -66.7m)
Total Stockholder Equity = 153.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.82% (Net Income -83.9m / Total Assets 218.4m)
RoE = -54.79% (Net Income TTM -83.9m / Total Stockholder Equity 153.2m)
RoCE = -50.02% (EBIT -83.8m / Capital Employed (Equity 153.2m + L.T.Debt 14.4m))
RoIC = -41.30% (negative operating profit) (NOPAT -66.2m / Invested Capital 160.4m)
WACC = 10.63% (E(701.3m)/V(717.2m) * Re(10.82%) + D(15.9m)/V(717.2m) * Rd(3.11%) * (1-Tc(0.21)))
Discount Rate = 10.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 23.69%
Fair Price DCF = unknown (Cash Flow -66.7m)
EPS Correlation: 84.12 | EPS CAGR: 67.93% | SUE: 4.0 | # QB: 2
Revenue Correlation: -41.59 | Revenue CAGR: -82.26% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.26 | Chg30d=+0.007 | Revisions Net=+3 | Analysts=7
EPS next Year (2026-12-31): EPS=-1.25 | Chg30d=+0.094 | Revisions Net=+3 | Growth EPS=-27.5% | Growth Revenue=-42.9%